News | April 5, 2022

INCOG BioPharma Completes Construction Of Cleanrooms, On Track To Manufacture Injectable Drug Products In Q3 2022

The project is part of an overall $100M investment in the new state-of-the-art facility and a step closer to readying the CGMP manufacturing capabilities to boost injectable drug product capacity

FISHERS, Ind. — INCOG BioPharma Services (“INCOG”), an Indiana-based contract development and manufacturing organization (CDMO) reached another major milestone in its facility by completing the construction of its cleanroom production area within the new 90,000 sq. ft. bio/pharmaceutical manufacturing site.

The fill-finish organization will be a key partner to life sciences companies that outsource the manufacturing of innovative injectable therapies. The newly completed cleanroom area within the building will feature a multi-use aseptic filling line, including fully integrated isolator technology, that can process both bulk vials and ready-to-use (RTU) vials, syringes, and cartridges. In addition, INCOG plans to conduct formulation activities, inspection, labeling, and packaging services in its recently constructed manufacturing space.

INCOG partnered with AES Clean Technology (“AES”), a leading provider of cleanroom facilities supporting the biopharmaceutical industry. AES equipped the new state-of-the-art facility in Fishers with its modular cleanroom systems and high-performance HVAC technology to optimize environmental control. The recently installed cleanroom systems provide INCOG with the flexibility and customization for growth, including the ability to quickly triple its drug product manufacturing and handling capacity via future capital investment projects.

With both speed-to-market and impact on patients in mind, INCOG has utilized an integrated design-delivery approach throughout the project to design, install, and commission its cleanroom in record time. AES has helped drive the process toward successful commissioning and qualification at every step of the way.

Grant Merrill, Chief Executive Officer of AES Clean Technology commented, “We are proud to partner with INCOG and support their mission of creating a better path to market for life-saving drugs through the therapies that they manufacture inside our cleanroom facilities.”

INCOG’s Vice President of Operations, Alex Haig, who steered the project, said, “I’m thankful for our partners at AES, Shiel Sexton, Javan Engineering, OPTIMA Pharma, and extended teams. INCOG is now even closer to opening our doors to advance therapies into the hands of patients and providers. The completion of the cleanroom space means we are ready to install our OPTIMA filling line and maintain our target to be CGMP ready by Q3 2022. With growing demand for injectables, our team is well positioned and ready to help alleviate capacity constraints in the global markets.”

INCOG has assembled a team with deep domain experience and knowledge in the formulation, development, and manufacturing of injectable medicines. The company has hired nearly 50 people in the last several months and plans to add another 50 positions by the end of 2023. Recently recognized as a “Best Place to Work” by the Indiana Chamber of Commerce, INCOG provides an entrepreneurial culture that fosters collaboration and promotes genuine teamwork. For more information surrounding career opportunities with INCOG, please visit

About INCOG BioPharma Services

Designed to deliver better. Discover the INCOG way.

INCOG has been designed and built from decades of experience, with a clear purpose: to deliver better CDMO services in the injectable drug product space. With our experienced team, best-in-class processes, and state-of-the-art equipment, we deliver meaningful results and stand-out customer experiences. We are here to strive for the best – for our team and for our customers. We are in it with you from the moment we start work on your project. We go above and beyond to understand your requirements, meet your needs, and foster a truly collaborative partnership.

INCOG offers development and manufacturing services to both early phase and late phase biopharmaceutical companies. The company’s service offering includes filling drug product into vials, syringes, and cartridges. INCOG also offers support services to include formulation development, analytical development, stability testing and storage, and final inspection, labeling, packaging, and device assembly.

For more information, please contact:

Miles Johnson, Manager, Corporate Development

Source: INCOG BioPharma Services